These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33410096)

  • 1. Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells.
    Feng J; Xu H; Cinquina A; Wu Z; Chen Q; Zhang P; Wang X; Shan H; Xu L; Zhang Q; Sun L; Zhang W; Pinz KG; Wada M; Jiang X; Hanes WM; Ma Y; Zhang H
    Stem Cell Rev Rep; 2021 Apr; 17(2):652-661. PubMed ID: 33410096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells.
    Feng J; Xu H; Cinquina A; Wu Z; Zhang W; Sun L; Chen Q; Tian L; Song L; Pinz KG; Wada M; Jiang X; Hanes WM; Ma Y; Zhang H
    Front Immunol; 2022; 13():997482. PubMed ID: 36172388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas.
    Hill LC; Rouce RH; Wu MJ; Wang T; Ma R; Zhang H; Mehta B; Lapteva N; Mei Z; Smith TS; Yang L; Srinivasan M; Burkhardt PM; Ramos CA; Lulla P; Arredondo M; Grilley B; Heslop HE; Brenner MK; Mamonkin M
    Blood; 2024 Mar; 143(13):1231-1241. PubMed ID: 38145560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies.
    Wada M; Zhang H; Fang L; Feng J; Tse CO; Zhang W; Chen Q; Sha S; Cao Y; Chen KH; Pinz KG; Chen X; Fan XX; Jiang X; Ma Y
    Stem Cell Rev Rep; 2020 Apr; 16(2):369-384. PubMed ID: 32008159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mRNA-Engineered CD5-CAR-γδT
    Zhu Z; Li H; Lu Q; Zhang Z; Li J; Wang Z; Yang N; Yu Z; Yang C; Chen Y; Lu H; Wang W; Niu T; Nie C; Tong A
    Adv Sci (Weinh); 2024 Sep; 11(35):e2400024. PubMed ID: 39013083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
    Huang YH; Wan CL; Dai HP; Xue SL
    Ann Hematol; 2023 Aug; 102(8):2001-2013. PubMed ID: 37227492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Chen KH; Wada M; Pinz KG; Liu H; Lin KW; Jares A; Firor AE; Shuai X; Salman H; Golightly M; Lan F; Senzel L; Leung EL; Jiang X; Ma Y
    Leukemia; 2017 Oct; 31(10):2151-2160. PubMed ID: 28074066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
    Ataca Atilla P; McKenna MK; Tashiro H; Srinivasan M; Mo F; Watanabe N; Simons BW; McLean Stevens A; Redell MS; Heslop HE; Mamonkin M; Brenner MK; Atilla E
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia.
    Xie L; Ma L; Liu S; Chang L; Wen F
    Int Immunopharmacol; 2021 Jul; 96():107731. PubMed ID: 33965880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A C
    Wu H; Yu Y; Zhao Y; Liu W; Liu Z; Zhang G; Chen Z
    Int Immunopharmacol; 2023 Nov; 124(Pt A):110904. PubMed ID: 37690234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
    Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
    Front Immunol; 2021; 12():728962. PubMed ID: 34691036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
    Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
    J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.
    Liu J; Zhang X; Zhong JF; Zhang C
    Immunotherapy; 2017 Oct; 9(13):1115-1125. PubMed ID: 29032733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4
    Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
    Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
    Kochenderfer JN; Somerville RPT; Lu T; Shi V; Bot A; Rossi J; Xue A; Goff SL; Yang JC; Sherry RM; Klebanoff CA; Kammula US; Sherman M; Perez A; Yuan CM; Feldman T; Friedberg JW; Roschewski MJ; Feldman SA; McIntyre L; Toomey MA; Rosenberg SA
    J Clin Oncol; 2017 Jun; 35(16):1803-1813. PubMed ID: 28291388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.